CASE
A 77‐year‐old woman presented to our hospital with progressive cognitive decline. Laboratory tests were significant for corrected calcium of 12.3 mg/dL reference (range: 8.8‐10.1 mg/dL), phosphate of 2.4 mg/dL (range: 2.7‐4.6 mg/dL), and elevated intact parathyroid hormone of 549 pg/mL (range: 10‐65 pg/mL). Renal function was normal; a thyroid ultrasound demonstrated no tumors. Noncontrast computed tomography (CT) revealed a mass measuring 2 cm in diameter in the posterior mediastinum (Figure A, arrow). Contrast enhanced CT demonstrated a well‐defined enhancing mass (Figure A, yellow arrow). 131I‐methoxyisobutyl isonitrile (MIBI) single‐photon emission computed tomography SPECT) showed specific uptake in the mass (Figure B, arrowheads). Because her cognitive impairment was persistent despite the administration of calcitonin plus normal saline infusion, she underwent surgical resection of ectopic mediastinal parathyroid adenoma. Her symptoms improved postoperatively, and she reverted to eucalcemia.
Horizontal view of noncontrast computed tomography (CT) of the mass (A, arrow). Contrast CT demonstrated enhancing mass measuring 2 cm in diameter in the posterior mediastinum (A, yellow arrow). 131I‐MIBI SPECT showed uptake in the mass (B, arrowheads)
Ectopic parathyroid adenoma causes approximately 6% of all hyperparathyroidism cases, which is not uncommon. However, the diagnosis of ectopic parathyroid is often missed because of vague symptoms such as cognitive dysfunction due to hypercalcemia. It frequently occurs in the thymus and mediastinum. Because the sensitivity and specificity of identifying parathyroid adenoma with a single modality were low regardless of the technique, it should be considered to include chest CT and 131I‐MIBI SPECT examinations in patients with possible hyperparathyroidism and normal thyroid ultrasound.
CONFLICT OF INTEREST
None declared.
AUTHOR CONTRIBUTION
YN involved in literature search and drafting. AY involved in clinical care of the patient and revision. MT involved in clinical care of the patient and revision. FO involved in revision.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Key Clinical Message
When you see a patient with cognitive dysfunction, hypercalcemia due to hyperparathyroidism is an important differential diagnosis. It is important to consider including chest computed tomography and 131I‐MIBI SPECT examinations in patients with possible hyperparathyroidism and normal thyroid ultrasound.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer





